Nxera Pharma.
$8.22
3
+$0+0% Friday 14:59
统计数据
当日最高
9.46
当日最低
9.46
52周最高
13.43
52周最低
8.56
成交量
100
平均成交量
33
市值
865.67M
市盈率
-
股息收益率
-
股息
-
即将到来
股息
0%股息收益率
10年增长
N/A
5年增长
N/A
3年增长
N/A
1年增长
N/A
收益
11Nov预期
预期每股收益
-0.043065972288
实际每股收益
N/A
人们还关注
此列表基于关注SOLTF的Stock Events用户的观察列表。这不是投资建议。
竞争者
这个列表是基于最近市场事件的分析。这不是投资建议。
Pfizer
PFE
市值164.39B
Merck
MRK
市值300.25B
Johnson & Johnson
JNJ
市值399.26B
GSK
GSK
市值89.55B
Novartis
NVS
市值244.75B
Abbvie
ABBV
市值346.75B
Bristol-Myers Squibb
BMY
市值101.27B
Sanofi
SNY
市值141.43B
Lilly(Eli) &
LLY
市值864.43B
Teva- Pharmaceutical Industries
TEVA
市值21.38B
关于
Pharmaceuticals: Generic
Health Technology
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical study; HTL0016878 for neurological diseases; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; and TMP301 and BHV3100 for neurological disorders, which is in clinical trials. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
Show more...
首席执行官
Shinichi Tamura
员工
360
国家
JP
ISIN
JP3431300007